-
ClouDr Receives NMPA Green Light for ClouDT-01, a Groundbreaking Digital Diabetes Treatment
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the banner of “ClouDr” on the Hong Kong stock exchange (HKG: 9955), has announced that it has secured marketing approval from the National Medical Products Administration (NMPA) for its innovative digital medicine product, ClouDT-01, designed for the treatment of diabetes. Leveraging…
-
Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong Kong Stock Exchange (HKG: 9955), has reported its financial results for the first half of 2024, demonstrating a robust year-on-year (YOY) increase of 17.9%, with total revenues reaching RMB 2.125 billion (USD 298 million). The…
-
ClouDr Secures Exclusive Sub-Licensing Rights for Iloprost Infusion Solution
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), operating under the brand name “ClouDr,” has announced a licensing agreement with Clinect Pty Ltd as the licensor and Bluefly Consulting Limited as the seller. ClouDr has secured exclusive sub-licensing rights for the development, manufacturing, promotion, publicity, distribution, and marketing of…
-
ClouDr Launches Dapagliflozin, Generic Version of AstraZeneca’s Forxiga, After NMPA Approval
•
Hangzhou Kang Ming Information Technology Co., Ltd. (HKG: 9955), known as “ClouDr,” has officially launched dapagliflozin, its self-operated product with marketing rights. This drug serves as a generic version of AstraZeneca (NASDAQ: AZN)’s Forxiga, a leading treatment for type 2 diabetes. The approval for dapagliflozin was secured through Nanjing F&S…
-
ClouDr Inks Deal with CR Sanjiu to Boost Hospital Sales of Cardiovascular Medicine
•
Hangzhou Kang Ming Information Technology Co., Ltd, (HKG: 9955) trading under the moniker “ClouDr”, has entered into a partnership with CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company specializing in treatments for cardiovascular and cerebrovascular diseases and endocrine disorders. Under this strategic alliance, ClouDr will serve as the general agent…
-
ClouDr Partners with Yangtze River Pharmaceutical to Digitize Chronic Disease Marketing
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading as “ClouDr” (HKG: 9955), has entered into a partnership with fellow Chinese company Yangtze River Pharmaceutical (Group) Co., Ltd. The collaboration will concentrate on providing digitalized marketing services within specific chronic disease sectors, with both parties looking to expand and deepen their…
